Central Diabetes Insipidus
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The increased incidence and severity of Clostridium difficile infection (CDI) are thought to result partly from the emergence of the hypervirulent BI/NAP1/027 strain.
|
29174729 |
2018 |
Clostridium; difficile (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
Diversity of multidrug-resistant epidemic Clostridium difficile NAP1/RT027/ST01 strains in tertiary hospitals from Honduras.
|
29890209 |
2018 |
Clostridium; difficile (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
Poor yield of Clostridium difficile testing algorithms using glutamate dehydrogenase antigen and C. difficile toxin enzyme immunoassays in a pediatric population with declining prevalence of clostridium difficile strain BI/NAP1/027.
|
29567127 |
2018 |
Clostridium; difficile (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prevalence of the Clostridium difficile BI/NAP1/027 strain across the United States Veterans Health Administration.
|
29174729 |
2018 |
Clostridium difficile infection
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Impact of the NAP-1 strain on disease severity, mortality, and recurrence of healthcare-associated Clostridium difficile infection.
|
28645479 |
2017 |
Clostridium difficile infection
|
0.100 |
Biomarker
|
disease |
BEFREE |
An outbreak of Clostridium difficile infection (CDI) caused by ribotype 027 (B1/NAP1) began in our hospital in November 2014, and produced 141 episodes in the following months.
|
28501926 |
2017 |
Central Diabetes Insipidus
|
0.100 |
Biomarker
|
disease |
BEFREE |
An outbreak of Clostridium difficile infection (CDI) caused by ribotype 027 (B1/NAP1) began in our hospital in November 2014, and produced 141 episodes in the following months.
|
28501926 |
2017 |
Central Diabetes Insipidus
|
0.100 |
Biomarker
|
disease |
BEFREE |
The NAP1 strain did not increase disease severity, mortality, or recurrence in this study, although the incidence of NAP1-positive healthcare associated-CDI was low.
|
28645479 |
2017 |
Central Diabetes Insipidus
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent outbreaks of CDI have been associated with the emergence of hypervirulent strains, such as NAP1/BI/027, many strains of which also produce a third toxin, binary toxin (CDTa and CDTb).
|
28125650 |
2017 |
Clostridium; difficile (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
Importantly, ecteinamycin demonstrated potent activity against the toxigenic strain of Clostridium difficile NAP1/B1/027 (MIC = 59 ng/μL), as well as other toxigenic and nontoxigenic C. difficile isolates both in vitro and in vivo.
|
28708379 |
2017 |
Clostridium; difficile (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
Development of a Novel Vaccine Containing Binary Toxin for the Prevention of Clostridium difficile Disease with Enhanced Efficacy against NAP1 Strains.
|
28125650 |
2017 |
Clostridium difficile infection
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Fluoroquinolone and Macrolide Exposure Predict Clostridium difficile Infection with the Highly Fluoroquinolone- and Macrolide-Resistant Epidemic C. difficile Strain BI/NAP1/027.
|
26525793 |
2016 |
Clostridium; difficile (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
Comparison of Multilocus Sequence Typing and the Xpert C. difficile/Epi Assay for Identification of Clostridium difficile 027/NAP1/BI.
|
26699700 |
2016 |
Clostridium; difficile (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
Comparative analysis of the Clostridium difficile BI/NAP1/027 strain R20291 and ClosTron-derived ermB mutants in the hamster infection model are compromised by the clindamycin susceptibility of the parent.Mutants can appear more virulent.
|
26946361 |
2016 |
Clostridium; difficile (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
The rapid spread of Clostridium difficile NAP1/BI/027 (C. difficile 027) has become one of the leading threats of healthcare-associated infections worldwide.
|
27411304 |
2016 |
Clostridium; difficile (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clinical Utility of Laboratory Detection of Clostridium difficile Strain BI/NAP1/027.
|
26511742 |
2016 |
Central Diabetes Insipidus
|
0.100 |
Biomarker
|
disease |
BEFREE |
The BI/NAP1/027 strain caused CDI in only 1 patient.
|
25782900 |
2015 |
Clostridium; difficile (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clostridium difficile NAP1/ribotype 027 is associated with severe disease and high mortality rates.
|
25915544 |
2015 |
Clostridium; difficile (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
Rapid spread of Clostridium difficile NAP1/027/ST1 in Chile confirms the emergence of the epidemic strain in Latin America.
|
25687254 |
2015 |
Clostridium difficile infection
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clostridium difficile infection after allogeneic hematopoietic stem cell transplant: strain diversity and outcomes associated with NAP1/027.
|
24973628 |
2014 |
Central Diabetes Insipidus
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Over 75 % of CDIs with NAP1 was hospital-acquired, and more often proceeded with generalized infection (p < 0.05).
|
24213847 |
2014 |
Clostridium difficile infection
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The NAP1/BI/027 strain causes more-severe disease than other widely prevalent strains and affects patients who were not traditionally thought to be at risk for Clostridium difficile infection.
|
23182524 |
2013 |
Clostridium; difficile (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
Real-time polymerase chain reaction method for detection of toxigenic Clostridium difficile from stools and presumptive identification of NAP1 clone.
|
23182075 |
2013 |
Clostridium; difficile (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
Association of relapse of Clostridium difficile disease with BI/NAP1/027.
|
23052318 |
2012 |
Central Diabetes Insipidus
|
0.100 |
Biomarker
|
disease |
BEFREE |
The gold standard was the toxigenic culture for the diagnosis of CDI and PCR ribotyping for the identification of the NAP1/027/BI strain.
|
21487764 |
2011 |